<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>67 Interleukins, Growth Factors And Targeted Therapies - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">30</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "text": "What is the mechanism of action of imatinib mesylate?",
    "choices": [
      {
        "id": 1,
        "text": "Increase in metabolism of P glycoprotein"
      },
      {
        "id": 2,
        "text": "Blocking the action of P glycoprotein"
      },
      {
        "id": 3,
        "text": "Blocks the action of chimeric fusion protein of BCR-ABL"
      },
      {
        "id": 4,
        "text": "Non-competitive inhibition of ATP binding site"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Imatinib</strong> mesylate <strong>blocks</strong> the action of the&nbsp;<strong>chimeric</strong> <strong>fusion protein</strong> of BCR-ABL. It targets the <strong>BCR-ABL tyrosine kinase</strong> and inhibits the activity of the fusion protein.</p>\n<p>A single molecular event, <strong>9:22 translocation</strong>, leads to the expression of the Abelson proto-oncogene kinase (ABL) fused to BCR (breakpoint cluster region) yielding a constitutively activated protein kinase in chronic myelogenous leukemia.&nbsp;Imatinib causes remission in &gt;90% of patients in the chronic phase of CML.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is not a BCR-ABL tyrosine kinase inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Bosutinib"
      },
      {
        "id": 2,
        "text": "Dasatinib"
      },
      {
        "id": 3,
        "text": "Erlotinib"
      },
      {
        "id": 4,
        "text": "Nilotinib"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Erlotinib</strong> is an epidermal growth factor receptor (<strong>EGFR</strong>) <strong>inhibitor.</strong></p>\n<p>Classification of&nbsp;<strong>BCR-ABL kinase inhibitors</strong>:&nbsp;</p>\n<ul>\n<li><strong>First-generation</strong>:<strong>&nbsp;</strong>most likely to develop resistance.\n<ul>\n<li>Imatinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Second generation</strong>: active against imatinib-resistant CML cases but not against T315I mutant cases.&nbsp;\n<ul>\n<li>Nilotinib</li>\n<li>Dasatinib&nbsp;</li>\n<li>Bosutinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Third generation</strong>: active against&nbsp;T315I mutant CML cases and other known mutant cases.&nbsp;\n<ul>\n<li>Ponatinib</li>\n</ul>\n</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient presented with abdominal pain. Imaging revealed a mass in the small intestine and a lesion in the liver. A diagnosis of a c-KIT positive gastrointestinal stromal tumor with liver metastasis was made on further evaluation. What is the drug of choice?",
    "choices": [
      {
        "id": 1,
        "text": "Imatinib"
      },
      {
        "id": 2,
        "text": "Bevacizumab"
      },
      {
        "id": 3,
        "text": "Denosumab"
      },
      {
        "id": 4,
        "text": "Rituximab"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>The drug of choice for the management of a patient with a&nbsp;<strong>metastatic gastrointestinal stromal tumor</strong> is <strong>imatinib.&nbsp;</strong></p>\n<p>It is an <strong>oral</strong> anticancer drug that acts by <strong>inhibiting tyrosine kinase</strong> activated due to BCR-ABL fusion. It also inhibits other related tyrosine kinases and hence is used in the treatment of conditions like gastrointestinal stromal tumor (driven by a<strong> c-KIT mutation).</strong></p>\n<p>Imatinib is the agent of choice for GIST patients with metastatic disease and as adjuvant therapy for c-kit positive GIST.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with chronic myeloid leukemia was switched to nilotinib as he showed only partial response to imatinib therapy. What is the mechanism resulting in the loss of response?",
    "choices": [
      {
        "id": 1,
        "text": "Amplification of wild-type kinase gene"
      },
      {
        "id": 2,
        "text": "Increased efflux"
      },
      {
        "id": 3,
        "text": "Point mutations in kinase domain"
      },
      {
        "id": 4,
        "text": "Overexpression of MDR gene"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The given scenario is suggestive of the <strong>development</strong> of <strong>resistance</strong> to <strong>imatinib,</strong> which is a <strong>tyrosine kinase inhibitor</strong>. This condition arises due to <strong>point mutations</strong> in three separate regions of the <strong>kinase domain</strong>.</p>\n<p>The contact points between imatinib and the enzyme become sites of mutations in drug-resistant leukemic cells and hence these <strong>mutations prevent tight binding</strong> of the <strong>drug</strong> and lock the enzyme in its open configuration (the configuration in which it has access to the substrate and is enzymatically active).</p>\n<p>Mechanisms other than BCR-ABL kinase mutations play a minor role in resistance to imatinib. They include:</p>\n<ul>\n<li>Amplification of the wild-type kinase gene has been identified in some cases.</li>\n<li>Overexpression of MDR-gene leading to increased drug efflux transporter has been shown experimentally but not implicated in clinical resistance.</li>\n</ul>\n<p>Nilotinib retains inhibitory activity in the presence of most point mutations that confer resistance to imatinib.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Imatinib is indicated in which of the following patients?",
    "choices": [
      {
        "id": 1,
        "text": "2 and 4 only"
      },
      {
        "id": 2,
        "text": "1, 2 and 4"
      },
      {
        "id": 3,
        "text": "1 and 5 only"
      },
      {
        "id": 4,
        "text": "1, 3 and 5"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Imatinib</strong> is the agent of <strong>choice</strong> in&nbsp;patients with<strong> metastatic GIST</strong> and as <strong>adjuvant</strong> therapy for <strong>c-kit positive</strong> GIST.&nbsp;Imatinib also shows therapeutic benefits in patients with&nbsp;<strong>hypereosinophilia syndrome</strong> and<strong> dermatofibrosarcoma protuberans&nbsp;</strong>(driven by activating mutations in the PDGFR).</p>\n<p>Imatinib is an oral anticancer drug that acts by inhibiting tyrosine kinase activated due to ABL-BCR fusion.&nbsp;Imatinib also inhibits other kinases and hence is used in the above-mentioned conditions.</p>\n<p><strong class=\"ng-binding\">Indications for imatinib:</strong></p>\n<div class=\"panel-body ng-scope\">\n<ul>\n<li><strong>BCR-ABL kinase mutations:</strong>\n<ul>\n<li>Chronic myelogenous leukemia (CML)</li>\n<li>Acute lymphoblastic leukemia (ALL)</li>\n</ul>\n</li>\n</ul>\n<ul>\n<li><strong>C-KIT mutations - </strong>gastrointestinal stromal tumors (GIST)</li>\n</ul>\n<ul>\n<li><strong>PDGFR mutations:</strong>\n<ul>\n<li>Dermatofibrosarcoma protuberans</li>\n<li>Hypereosinophilia syndrome</li>\n<li>Chronic myelomonocytic leukemia (CML)</li>\n</ul>\n</li>\n</ul>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is a third generation BCR-ABL kinase inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Nilotinib"
      },
      {
        "id": 2,
        "text": "Bosutinib"
      },
      {
        "id": 3,
        "text": "Ponatinib"
      },
      {
        "id": 4,
        "text": "Dasatinib"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Ponatinib</strong> is a <strong>third-generation</strong> BCR-ABL kinase inhibitor.</p>\n<p>Classification of&nbsp;<strong>BCR-ABL kinase inhibitors</strong>:&nbsp;</p>\n<ul>\n<li><strong>First-generation</strong>: most likely to develop resitance.\n<ul>\n<li>Imatinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Second-generation</strong>: active against imatinib-resistant CML cases but not against T315I mutant cases.&nbsp;\n<ul>\n<li>Nilotinib</li>\n<li>Dasatinib&nbsp;</li>\n<li>Bosutinib&nbsp;</li>\n</ul>\n</li>\n<li><strong>Third-generation</strong>: active against&nbsp;T315I mutant CML cases and other known mutant cases.&nbsp;\n<ul>\n<li>Ponatinib</li>\n</ul>\n</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with trastuzumab-refractory breast cancer is started on lapatinib. Which of the following statements is true regarding this drug?",
    "choices": [
      {
        "id": 1,
        "text": "Dual inhibitor of VEGFR and HER 2 tyrosine kinase"
      },
      {
        "id": 2,
        "text": "Dual inhibitor of MET and HER 2 tyrosine kinase"
      },
      {
        "id": 3,
        "text": "Dual inhibitor of VEGFR and MET tyrosine kinase"
      },
      {
        "id": 4,
        "text": "Dual inhibitor of EGFR and HER 2 tyrosine kinase"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Lapatinib&nbsp;</strong>is a <strong>dual inhibitor</strong> of epidermal growth factor (<strong>EGFR</strong>) and human epidermal growth factor 2 (<strong>HER2</strong>) <strong>tyrosine kinase</strong>.</p>\n<p>Lapatinib in combination with capecitabine is approved for the treatment of patients with metastatic HER2-positive and trastuzumab-refractory <strong>breast cancer.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which among the following is an irreversible inhibitor of EGFR tyrosine kinase?",
    "choices": [
      {
        "id": 1,
        "text": "Gefitinib"
      },
      {
        "id": 2,
        "text": "Erlotinib"
      },
      {
        "id": 3,
        "text": "Trametinib"
      },
      {
        "id": 4,
        "text": "Afatinib"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Afatinib</strong> binds covalently with epidermal growth factor receptor tyrosine kinase (<strong>EGFR-TK</strong>) also known as Her-1 receptor and <strong>inhibits</strong> it <strong>irreversibly</strong>.&nbsp;It is approved for the use of <strong>metastatic non-small cell lung cancer.</strong></p>\n<p>Gefitinib and erlotinib compete with ATP binding to EGFR and results in competitive inhibition, which is reversible.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/5e5de2d60b9f4b5cb196af855a64327fx1280x1399.JPEG"
    ]
  },
  {
    "text": "A patient undergoing treatment for colon cancer develops hypertension. Which of the following drugs is most commonly implicated?",
    "choices": [
      {
        "id": 1,
        "text": "Trastuzumab"
      },
      {
        "id": 2,
        "text": "Bevacizumab"
      },
      {
        "id": 3,
        "text": "Panitumumab"
      },
      {
        "id": 4,
        "text": "Cetuximab"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Hypertension</strong> is one of the <strong>characteristic side effects</strong> of <strong>angiogenesis inhibitors</strong> like <strong>bevacizumab</strong>.&nbsp;</p>\n<p>The mechanism is not clear but may be related to<strong> decreased</strong> endothelial <strong>nitric oxide production</strong>.&nbsp;Patients receiving higher doses and prolonged treatment might require antihypertensive medications.</p>\n<p>Bevacizumab can be used in the treatment of metastatic colon cancer, in combination with FOLFOX or FOLFIRI regimen. It can also be used in the treatment of non-small cell lung cancer.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with uncontrolled diabetes is diagnosed to have diabetic macular edema. Which of the following anti-VEGF therapies is effective in the treatment of this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Bevacizumab"
      },
      {
        "id": 2,
        "text": "Ranibuzumab"
      },
      {
        "id": 3,
        "text": "Aflibercept"
      },
      {
        "id": 4,
        "text": "Ramucirumab"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Aflibercept</strong> is more effective in <strong>diabetic macular edema</strong> in patients with worse baseline values of visual impairment when compared to bevacizumab and ranibizumab.</p>\n<p>All of them are <strong>administered intravitreally</strong>. Clinical trials have shown the advantage of aflibercept over&nbsp;bevacizumab and ranibizumab in visual and anatomic terms at the end of one year.&nbsp;</p>\n<p>Ramucirumab which is a monoclonal antibody against VEGFR is not indicated for diabetic macular edema.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient is referred to your center for the management of hepatocellular carcinoma. Imaging reveals a large lesion in the liver with multiple intrahepatic metastases. The tumor is found to be unresectable. Which of the following is considered as first-line treatment for this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Sunitinib"
      },
      {
        "id": 2,
        "text": "Sorafenib"
      },
      {
        "id": 3,
        "text": "Regorafenib"
      },
      {
        "id": 4,
        "text": "Thalidomide"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Sorafenib</strong>&nbsp;is indicated as a first-line treatment for <strong>unresectable hepatocellular carcinoma</strong>. It&nbsp;is an <strong>angiogenesis</strong>&nbsp;<strong>inhibitor.</strong>&nbsp;</p>\n<p><strong>Hepatocellular carcinoma management:</strong></p>\n<ul>\n<li>Resection, ablation, and other physical measures are the mainstay.</li>\n<li>Only two drugs (angiogenesis inhibitors) are approved in this condition:\n<ul>\n<li><strong>Sorafenib</strong> (first-line)</li>\n<li><strong>Regorafenib</strong> (second-line).</li>\n</ul>\n</li>\n</ul>\n<p>Sunitinib and thalidomide are not indicated in hepatocellular carcinoma.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Thalidomide should not be used in which of the following conditions?",
    "choices": [
      {
        "id": 1,
        "text": "HIV-associated peripheral neuropathy"
      },
      {
        "id": 2,
        "text": "HIV-associated aphthous ulcers"
      },
      {
        "id": 3,
        "text": "Behcet syndrome"
      },
      {
        "id": 4,
        "text": "Erythema nodosum leprosum"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Thalidomide </strong>use is associated with<strong> peripheral neuropathy</strong> and is usually avoided in HIV-associated peripheral neuropathy as it can worsen the condition.</p>\n<p>It is being investigated as an <strong>orphan drug</strong> for:</p>\n<ul>\n<li>Recurrent aphthous ulcers</li>\n<li>GVHD</li>\n<li>Behcet syndrome</li>\n<li>primary brain malignancies</li>\n<li>Kaposi's sarcoma</li>\n<li>Crohn&rsquo;s disease.</li>\n</ul>\n<p>It is approved for use in multiple myeloma and erythema nodosum leprosum.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Use of lenalidomide over thalidomide would lead to the reduction of incidence of the following side effects, except ___________.",
    "choices": [
      {
        "id": 1,
        "text": "Constipation"
      },
      {
        "id": 2,
        "text": "Sedation"
      },
      {
        "id": 3,
        "text": "Neuropathy"
      },
      {
        "id": 4,
        "text": "Bone marrow suppression"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Lenalidomide,</strong> which is a congener of thalidomide,&nbsp;<strong>suppresses bone marrow</strong> and is associated with significant leukopenia.</p>\n<p>Lenalidomide use is associated with a&nbsp;<strong>lesser</strong>&nbsp;incidence of <strong>sedation, constipation,</strong> and <strong>neuropathy</strong> when compared to thalidomide.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is a proteasome inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Paclitaxel"
      },
      {
        "id": 2,
        "text": "Bortezomib"
      },
      {
        "id": 3,
        "text": "Cetuximab"
      },
      {
        "id": 4,
        "text": "Irinotecan"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Bortezomib</strong> is a proteasome inhibitor.</p>\n<p>It is a boron-containing <strong>anticancer</strong> drug that covalently binds to the proteasome and <strong>inhibits</strong> its <strong>proteolytic activity</strong>, thereby disrupting many intracellular signaling pathways<strong>.</strong> The most important of these is nuclear factor-&kappa;B (<strong>NF-&kappa;B</strong>) <strong>mediated signaling</strong>. It is indicated in the management of <strong>multiple myeloma</strong>.</p>\n<p>Option A: Paclitaxel is a taxane.</p>\n<p>Option C: Cetuximab is a monoclonal antibody against the extracellular domain of EGFR.</p>\n<p>Option D: Irinotecan is a topoisomerase I inhibitor.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs can be used for the treatment of a patient with hormone-responsive breast cancer?",
    "choices": [
      {
        "id": 1,
        "text": "Adriamycin"
      },
      {
        "id": 2,
        "text": "Clomiphene citrate"
      },
      {
        "id": 3,
        "text": "Diethylstilbestrol"
      },
      {
        "id": 4,
        "text": "Tamoxifen"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Tamoxifen</strong> is a <strong>selective estrogen receptor modulator</strong> that is indicated for <strong>hormone-responsive breast cancer.</strong>&nbsp;</p>\n<p>It is approved for endocrine treatment of women with ER+ metastatic breast cancer or following primary tumor excision as adjuvant therapy.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient undergoing adjuvant radiotherapy for an oral malignancy is prescribed a radioprotective drug. Identify this drug.",
    "choices": [
      {
        "id": 1,
        "text": "Cetuximab"
      },
      {
        "id": 2,
        "text": "Amifostine"
      },
      {
        "id": 3,
        "text": "Cisplatin"
      },
      {
        "id": 4,
        "text": "Gemcitabine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Amifostine</strong>&nbsp;is the <strong>radioprotective</strong> drug that has been prescribed to this patient.</p>\n<p>It is an organic thiophosphate cytoprotective agent that is <strong>indicated</strong> for the following conditions:</p>\n<ul>\n<li>Reduction of <strong>nephrotoxicity</strong> associated with <strong>cisplatin.</strong></li>\n<li>Reduction of <strong>xerostomia</strong> in patients with <strong>head</strong> and <strong>neck cancer</strong> undergoing postoperative irradiation.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which among the following is a cyclin-dependent kinase (CDK) 4/6 inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Ruxolitinib"
      },
      {
        "id": 2,
        "text": "Palbociclib"
      },
      {
        "id": 3,
        "text": "Cobimetinib"
      },
      {
        "id": 4,
        "text": "Trametinib"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Palbociclib</strong> is a <strong>cyclin-dependent kinase</strong> (CDK) 4/6 inhibitor.&nbsp;It is approved for use in <strong>advanced</strong> or <strong>metastatic ER-positive</strong>&nbsp;<strong>HER2-negative</strong>&nbsp;<strong>breast cancer.</strong>&nbsp;</p>\n<p>Ruxolitinib is an inhibitor of Janus associated kinases: JAK1 and JAK2.&nbsp;</p>\n<p>Tramitenib and cobimetinib are inhibitors of serine-threonine kinases.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following inhibits  V600E mutated BRAF?",
    "choices": [
      {
        "id": 1,
        "text": "Vemurafenib"
      },
      {
        "id": 2,
        "text": "Dabrafenib"
      },
      {
        "id": 3,
        "text": "Both A and B"
      },
      {
        "id": 4,
        "text": "Ibrutinib"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Vemurafenib</strong> and <strong>dabrafenib </strong>inhibit V600E mutated <strong>BRAF</strong> present in <strong>melanoma.</strong></p>\n<p>Both are indicated in the management of melanoma.&nbsp;</p>\n<p>The name <strong>vemuraf</strong>enib is derived from the target <strong>V</strong>600<strong>E</strong> <strong>mu</strong>tated B<strong>RAF</strong>.</p>\n<p>Ibrutinib is a Bruton tyrosine kinase inhibitor.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which among the following is a hedgehog pathway inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Vemurafenib"
      },
      {
        "id": 2,
        "text": "Vismodegib"
      },
      {
        "id": 3,
        "text": "Olaparib"
      },
      {
        "id": 4,
        "text": "Neratinib"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Vismodegib</strong> acts as a competitive <strong>antagonist</strong> of the SMO (smoothens hedgehog) receptor in the <strong>hedgehog signaling pathway</strong>.&nbsp;</p>\n<p>Hedgehog signaling plays a key role in stem cell regulation and tissue regeneration. Basal cell carcinoma (BCC) is associated with dysregulation of this pathway. Vismodegib is indicated in patients with <strong>metastatic</strong> or<strong> relapsed BCC.&nbsp;</strong></p>\n<p>Option A:&nbsp;Vemurafenib is a BRAF kinase inhibitor.&nbsp;</p>\n<p>Option C:&nbsp;Olaparib is an inhibitor of PARP [Poly (ADP-ribose) polymerase] enzyme.&nbsp;</p>\n<p>Option D:&nbsp;Neratinib is an irreversible inhibitor of HER-2 and EGFR.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Evaluation of a patient with CLL  showed evidence of 17p deletion. Which of the following is a BCL-2 inhibitor approved for use in this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Olaparib"
      },
      {
        "id": 2,
        "text": "Rucaparib"
      },
      {
        "id": 3,
        "text": "Venetoclax"
      },
      {
        "id": 4,
        "text": "Vismodegib"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Venetoclax</strong> is a small-molecule <strong>inhibitor</strong> of <strong>BCL-2</strong> that is approved for use in <strong>CLL</strong> with a 17p deletion.</p>\n<p>Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival.&nbsp;Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing proapoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases.</p>\n<p>Olaparib and rucaparib are inhibitors of PARP [Poly (ADP-ribose) polymerase] enzymes.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Sipuleucel-T is the first vaccine approved for the treatment of cancer. This vaccine induces an immune response against which of the following?",
    "choices": [
      {
        "id": 1,
        "text": "HER2 receptors"
      },
      {
        "id": 2,
        "text": "Prostatic acid phosphatase"
      },
      {
        "id": 3,
        "text": "Vascular endothelial growth factor"
      },
      {
        "id": 4,
        "text": "Vascular endothelial growth factor receptor"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Sipuleucel-T</strong> is a cell-based approach to <strong>induce</strong> an <strong>immune response</strong> against<strong> prostatic acid phosphatase</strong> (PAP) that is commonly expressed in<strong> prostatic cancer.</strong> It is approved for use in minimally symptomatic, hormone-refractory, metastatic prostate cancer.&nbsp;</p>\n<p>Sipuleucel-T preparation is done by isolating a patient's peripheral blood cells by leukapheresis and then exposing them to PAP-GM-CSF (which is a human recombinant protein). When these treated cells are infused to a patient, the APCs present in the blood produces antibodies directed against PAP.</p>\n<p>Prostate-specific membrane antigen (PSMA) is a specific prostate epithelial cell membrane antigen, showing increased expression in prostate cancers, which is also a&nbsp;potential target for monoclonal antibody therapy.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is not a histone deacetylase inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Vorinostat"
      },
      {
        "id": 2,
        "text": "Romidepsin"
      },
      {
        "id": 3,
        "text": "Panabinostat"
      },
      {
        "id": 4,
        "text": "Febuxostat"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Febuxostat </strong>is a uric acid synthesis inhibitor that acts by<strong> inhibiting </strong>the enzyme<strong> xanthine oxidase</strong>&nbsp;and it is indicated in gout management.</p>\n<p>Examples of <strong>histone deacetylase inhibitors</strong> are:</p>\n<ul>\n<li>Vorinostat - cutaneous T cell lymphoma</li>\n<li>Belinostat - peripheral T cell lymphoma</li>\n<li>Romidepsin - cutaneous/peripheral T cell lymphoma</li>\n<li>Panobinostat - multiple myeloma</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 60-year-old woman was diagnosed with melanoma. Sentinel lymph node biopsy showed malignant cells. Which of the following drugs used in this condition is a MEK inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "Dabrafenib"
      },
      {
        "id": 2,
        "text": "Vemurafenib"
      },
      {
        "id": 3,
        "text": "Trametinib"
      },
      {
        "id": 4,
        "text": "Ipilimumab"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>The scenario is suggestive of <strong>metastatic melanoma</strong> and<strong> trametinib</strong> is used in this condition. It is a <strong>reversible inhibitor</strong> of the mitogen-activated extracellular signal-regulated kinase (<strong>MEK</strong>). It inhibits the serine-threonine kinase domain of BRAF V600E mutant of MEK.</p>\n<p>It can be used as a <strong>single agent</strong> but it is more effective when used with BRAF inhibitors like dabrafenib.</p>\n<p><strong>Adverse effects</strong> of this drug include:&nbsp;</p>\n<ul>\n<li>Cutaneous rash</li>\n<li>Acneiform dermatitis</li>\n<li>Diarrhea</li>\n<li>Fatigue</li>\n<li>Nausea</li>\n<li>Lymphedema.</li>\n<li>Cardiomyopathy</li>\n<li>Hypertension</li>\n<li>Hemorrhage</li>\n<li>Interstitial lung disease</li>\n<li>Ocular toxic effects.</li>\n</ul>\n<p>Options A and B: Dabrafenib and vemurafenib are BRAF inhibitors used in metastatic melanoma.</p>\n<p>Option D: Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used in metastatic or unresectable melanoma.</p>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 4-year-old child who was being evaluated for pancytopenia is diagnosed with acute lymphoblastic leukemia. Which of the following is the first gene therapy-based treatment approved for use in this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Trastuzumab"
      },
      {
        "id": 2,
        "text": "Tisagenlecleucel"
      },
      {
        "id": 3,
        "text": "Riociguat"
      },
      {
        "id": 4,
        "text": "Dinutuximab"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Tisagenlecleucel </strong>is the first <strong>gene therapy-based treatment</strong> that is approved for use in<strong> acute lymphoblastic leukemia (ALL).</strong></p>\n<p>The therapy involves reprogramming a patient&rsquo;s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) to identify and eliminate <strong>CD19-</strong>expressing malignant and normal cells.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 67-year-old man presented with fatigue and weight loss. On examination, pallor and splenomegaly were noted. Peripheral blood smear examination findings are shown in the image. Which of the following BCR-ABL tyrosine kinase inhibitors is not a first-line agent for this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Imatinib"
      },
      {
        "id": 2,
        "text": "Dasatinib"
      },
      {
        "id": 3,
        "text": "Nilotinib"
      },
      {
        "id": 4,
        "text": "Bosutinib"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The given scenario and the peripheral smear findings (increased WBCs with myelocytes, metamyelocytes, and band forms), is suggestive of chronic myelogenous leukemia (<strong>CML</strong>).&nbsp;<strong>Bosutinib</strong>&nbsp;is approved for use in this condition<strong>&nbsp;</strong>only for<strong> resistant and/or intolerant </strong>cases and not in newly diagnosed cases.</p>\n<p>Agents that can be used as first-line for CML are:</p>\n<ul>\n<li>Imatinib</li>\n<li>Dasatinib</li>\n<li>Nilotinib&nbsp;</li>\n</ul>\n<p>Dasatinib and nilotinib can be used in newly diagnosed cases of CML, that are found to be imatinib-resistant.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/7470297a361d4f2f98615f96cafa7386.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "A 63-year-old postmenopausal woman came to the OPD with a 12 cm adnexal mass. Her CA-125 levels were raised and her risk of malignancy index was calculated to be 250. PET scan revealed hepatic metastases. Which PARP inhibitor can you use in her treatment?",
    "choices": [
      {
        "id": 1,
        "text": "Palbociclib"
      },
      {
        "id": 2,
        "text": "Rucaparib"
      },
      {
        "id": 3,
        "text": "Vorinostat"
      },
      {
        "id": 4,
        "text": "Romidepsin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p style=\"text-align: justify;\">The clinical scenario points towards a diagnosis of metastatic ovarian cancer.<strong> Rucaparib</strong> is a poly ADP-ribose polymerase/ <strong>PARP</strong> <strong>inhibitor&nbsp;</strong>approved for the&nbsp;treatment of&nbsp;<strong>advanced ovarian cancer.</strong></p>\n<p style=\"text-align: justify;\">PARP is a nuclear protein that transfers ADP-ribose from NAD<sup><span class=\"s1\">+ </span></sup>to target proteins and this plays an important&nbsp;role in the DNA damage response. Rucaparib and <strong>olaparib</strong> are PARP inhibitors.</p>\n<p style=\"text-align: justify;\">Option A: Palbociclib&nbsp;is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. It is used in the treatment of metastatic breast cancer.&nbsp;</p>\n<p style=\"text-align: justify;\">Options C &amp; D: Vorinostat and romidepsin are histone deacetylase inhibitors.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following conditions has hydrogen peroxide been recently approved for?",
    "choices": [
      {
        "id": 1,
        "text": "Psoriasis"
      },
      {
        "id": 2,
        "text": "Rosacea"
      },
      {
        "id": 3,
        "text": "Atopic eczema"
      },
      {
        "id": 4,
        "text": "Seborrheic keratoses"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p style=\"text-align: left;\">A <strong>topical</strong> solution of<strong>&nbsp;hydrogen peroxide</strong>&nbsp;has been approved for the treatment of <strong>raised seborrheic keratoses</strong>.</p>\n<p style=\"text-align: left;\">Hydrogen peroxide is a <strong>keratolytic agent</strong>. Its exact mechanism of action in the treatment of seborrheic keratoses<strong>&nbsp;</strong>is not fully understood. Supraphysiologic concentrations may cause oxidative damage and death to seborrheic keratosis cells.</p>\n<p style=\"text-align: left;\">Hydrogen peroxide is commonly used as a <strong>disinfectant</strong> to <strong>clean wounds</strong>. It can also be used as a <strong>mouthwash</strong>.&nbsp;</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following conditions is apalutamide approved for?",
    "choices": [
      {
        "id": 1,
        "text": "Breast cancer"
      },
      {
        "id": 2,
        "text": "Colon cancer"
      },
      {
        "id": 3,
        "text": "Prostate cancer"
      },
      {
        "id": 4,
        "text": "Gastric cancer"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Apalutamide</strong>&nbsp;is an&nbsp;<strong>androgen receptor inhibitor</strong> indicated for the treatment of patients with non-metastatic castration-resistant<strong> prostate cancer.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 60-year-old woman was diagnosed with melanoma. Sentinel lymph node biopsy showed malignant cells.  Which among the following is a recombinant interleukin-2 preparation approved for use in this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Denileukin diftitox"
      },
      {
        "id": 2,
        "text": "Aldesleukin"
      },
      {
        "id": 3,
        "text": "Imatinib"
      },
      {
        "id": 4,
        "text": "Nilotinib"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The clinical scenario is suggestive of <strong>metastatic melanoma</strong>.&nbsp;The recombinant interleukin-2 (IL-2) preparation that is approved for use in metastatic melanoma is&nbsp;<strong>aldesleukin.</strong>&nbsp;It acts as an&nbsp;<strong>IL-2 agonist</strong> and is also approved for use in metastatic renal cell cancer.</p>\n<p><strong>Denileukin diftitox</strong> is an immunotoxin made from the recombinant combination of IL-2 and the catalytically active fragment of diphtheria toxin.&nbsp;It is approved for use in <strong>cutaneous T cell lymphoma.</strong></p>\n<p>Imatinib and nilotinib are a BCR/ABL tyrosine kinase inhibitor.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Denileukin diftitox, a drug approved for the treatment of recurrent/refractory cutaneous T-cell lymphomas, is an immunotoxin made of:",
    "choices": [
      {
        "id": 1,
        "text": "Fusion protein of IL-2 and pertussis toxin"
      },
      {
        "id": 2,
        "text": "Fusion protein of IL-2 and diptheria toxin"
      },
      {
        "id": 3,
        "text": "Monoclonal antibody against CD33"
      },
      {
        "id": 4,
        "text": "Monoclonal antibody against CD30"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Denileukin diftitox</strong> is an <strong>immunotoxin</strong> made from the genetic recombination of <strong>IL-2</strong> and the catalytically active fragment of <strong>diphtheria toxin</strong>.&nbsp;</p>\n<p>It is indicated for advanced <strong>cutaneous T-cell lymphoma</strong> in patients with &gt;20% of T cells expressing the surface marker CD25.&nbsp;After binding to the IL-2 receptors, it is internalized by endocytosis.&nbsp;The active fragment of <strong>diphtheria toxin</strong> then is released into the cytosol, where it <strong>inhibits protein synthesis</strong> through ADP ribosylation, leading to <strong>cell death</strong>.</p>\n<p>Immunotoxins are proteins that contain a toxin along with an antibody that binds specifically to target cells.</p>\n<p><strong>Antibody-drug conjugates</strong> are complex molecules composed of an&nbsp;antibody&nbsp;linked to a biologically active&nbsp;cytotoxic&nbsp;(anticancer) drug. These antibody-targeted drug therapies are cell-specific to kill efficiently the target cells that bind and internalize the drug conjugate. Examples are:</p>\n<dl class=\"article-list\">\n<dt></dt>\n</dl>\n<ul>\n<li><strong>Gemtuzumab&nbsp;ozogamicin -&nbsp;</strong>Monoclonal antibody against CD33 linked to a semisynthetic derivative of calicheamicin, a potent antitumor antibiotic.&nbsp;It was approved for the treatment of acute myeloid leukemia.</li>\n<li class=\"p1\"><strong>Brentuximab vedotin -&nbsp;</strong>Anti-CD30 IgG1 monoclonal antibody linked with the microtubule-disrupting agent MMAE.&nbsp;It is used for the treatment of Hodgkin and anaplastic lymphoma.</li>\n<li class=\"p1\"><strong>Ado-trastuzumab emtansine -&nbsp;</strong>It<strong>&nbsp;</strong>combines the HER2-targeted properties of trastuzumab with the antimicrotubule agent DM1 (derived from maytansine), allowing preferential intracellular drug delivery to HER2+ cells.&nbsp;It is used in the treatment of HER+ breast cancer.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  }
];
        let quizName = '67 Interleukins, Growth Factors And Targeted Therapies';
        let hierarchy = ["Marrow", "qBank", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>